In vivo experiments revealed that CrkL silencing suppressed tumor growth of K562/ADR through regulating PI3K/AKT/MRP1 signaling.Together, we indicated that CrkL is up‐regulated in myelogenous leukemia cells and silencing of CrkL could reversed Doxorubicin resistance effectively. Here, CRKL is linked to myeloid leukemia.